Impact of the CATIE findings on state mental health policy

Psychiatric Services

Volumn 59, Issue 5, 2008, Pages 534-536

  Parks, Joseph J ^a   Radke, Alan Q ^b   Tandon, Rajiv ^c  

^a MISSOURI DEPARTMENT OF HEALTH AND SENIOR SERVICES   (United States)

^b Minnesota Department of Human Services   (United States)

^c Florida Department of Children and Families   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE;

CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG UTILIZATION; EXTRAPYRAMIDAL SYNDROME; HEALTH CARE POLICY; MENTAL HEALTH; PRESCRIPTION; SCHIZOPHRENIA; SHORT SURVEY;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; HEALTH PLANNING GUIDELINES; HEALTH POLICY; HUMANS; MEDICAID; MENTAL HEALTH SERVICES; SCHIZOPHRENIA; STATE GOVERNMENT; UNITED STATES;

EID: 50849102324     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/appi.ps.59.5.534     Document Type: Short Survey

References (17)

1. Radke A, Parks J, Parker G, et al: Principles of antipsychotic prescribing for policy makers: the comparative effectiveness of available antipsychotic medications. Schizophrenia Bulletin, in press
2. Lieberman JA, Stroup ST, McEvoy JP, et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353:1209-1223, 2005
3. Heres S, Davis J, Maino K, et al: Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. American Journal of Psychiatry 163:185-194, 2006
4. McEvoy JP, Lieberman JA, Stroup TS, et al: Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior antipsychotic treatment. American Journal of Psychiatry 163:600-610, 2006
5. Stroup TS, Lieberman JA, McEvoy JP, et al: Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. American Journal of Psychiatry 163:611-622, 2006
6. Rosenheck RA, Leslie DL, Sindelar J, et al: Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. American Journal of Psychiatry 163:2080-2089, 2006
7. Keefe RSE, Bilder RM, Davis SM, et al: Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Archives of General Psychiatry 64:633-647, 2007
8. Swartz MS, Perkins DO, Stroup ST, et al: Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. American Journal of Psychiatry 164:428-436, 2007
9. Kane JM, Leucht S, Carpenter D, et al: Expert Consensus Guideline Series: optimizing pharmacologic treatment of psychotic disorders. Journal of Clinical Psychiatry 64(suppl 12):1-100, 2003
10. Falkai P, Wobrock T, Lieberman J, et al: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia: part 1. acute treatment of schizophrenia. World Journal of Biological Psychiatry 6:132-191, 2005
11. Polinski JM, Wang Ps, Fischer MA: Medicaid's prior authorization program and access to atypical antipsychotic medications. Health Affairs 26:750-760, 2007
12. Hugenholtz GW, Heerdink ER, Stolker JJ, et al: Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses. Journal of Clinical Psychiatry 67:897-903, 2006
13. Tandon R, Carpenter WT, Davis JM: Firstand second-generation antipsychotics: learning from CUtLASS and CATIE (reply to letter). Archives of General Psychiatry 64:977-980, 2007
14. Rosenheck R, Stroup ST, Keefe RSE, et al: Study samples key to assessing risk (reply to letter). Current Psychiatry 6:3-19, 2007
15. Tandon R, Moller H-J, Belmaker R, et al: World Psychiatry Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in schizophrenia. Schizophrenia Research, in press
16. Constantine RJ, Richard SM, Surles RC, et al: Optimizing pharmacotherapy of schizophrenia: tools for the psychiatrist. Current Psychosis and Therapeutics Reports 4:5-11, 2006
17. Parks J, Surles R: Using best practices to manage psychiatric medications under Medicaid. Psychiatric Services 55:1227-1229, 2004